Welcome to our dedicated page for NanoViricides news (Ticker: NNVC), a resource for investors and traders seeking the latest updates and insights on NanoViricides stock.
NanoViricides Inc. (NYSE American: NNVC) is a pioneering nano-biopharmaceutical company dedicated to the discovery, development, and commercialization of antiviral drugs targeting life-threatening viral infections. Utilizing advanced nanomedicine technologies, NanoViricides focuses on creating nanoviricide® drug candidates designed to attack and dismantle virus particles.
The company's diverse product pipeline includes:
- HerpeCide™ Program: Dermal topical and eye drops for treating shingles, post-herpetic neuralgia (PHN), chickenpox, herpes, recurrent herpes labialis, genital herpes, and ocular herpes keratitis.
- FluCide™: Broad-spectrum anti-influenza nanoviricide, available in injectable form for hospitalized patients and oral form for outpatients.
- DengueCide™: Treatment for all types of dengue viruses.
- HIVCide™: An escape-resistant anti-HIV nanoviricide.
One of NanoViricides' lead candidates, NV-387, has shown promising results against a wide range of viruses, including RSV, COVID-19, Long COVID, Influenza, Bird Flu H5N1, and smallpox/monkeypox. NV-387 has progressed to Phase II clinical trials for RSV treatment, having completed Phase I trials with no adverse events.
The company’s innovative technology platform mimics host-side features that viruses use to enter cells, making it unlikely for viruses to evade these drugs even with mutations. This breakthrough approach has resulted in NV-387 demonstrating superior efficacy compared to existing approved drugs in preclinical studies.
Financially, NanoViricides reported a cash balance of approximately $3.51 million as of March 31, 2024, with additional agreements bringing the total available cash to approximately $6 million. Despite facing challenges in clinical trials due to the waning COVID-19 pandemic, the company remains focused on advancing its pipeline, securing additional financing, and exploring partnerships to support its operations.
Recent news highlights significant progress with NV-387, including strong activity against various viruses, successful preclinical and clinical trial outcomes, and plans for further development. NanoViricides continues to drive innovation in antiviral therapy, aiming to meet unmet medical needs and revolutionize the treatment of viral infections.
Rhea-AI Summary
NanoViricides, Inc. (NNVC) has developed NV-CoV-2 oral drug products containing the active pharmaceutical ingredient NV-387, demonstrating strong safety and tolerability in clinical trials. The company believes that NV-387, an ultra-broad-spectrum antiviral nanomedicine, has long-term potential against many viruses, similar to antibiotics. The technology involves copying the host-side signature used by viruses to infect hosts, enabling a direct-acting antiviral that destroys the virus. NV-387 is designed to be active against a large number of viruses, with potential market sizes reaching billions of dollars. The strong safety and tolerability of NV-387 suggests it can be used across all patients, irrespective of age, co-morbidities, or disease severity, similar to antibiotics. NanoViricides aims to revolutionize antiviral treatment with NV-387.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.8%
Tags
-
Rhea-AI Summary
NanoViricides, Inc. (NNVC) successfully completed the Phase 1a/1b Clinical Trial of NV-CoV-2, reporting no adverse events. NV-387, the active ingredient, demonstrated excellent safety and broad-spectrum antiviral activity. The results indicate a promising potential for rapid response to pandemics and treatment of viral infections. The trial was managed by Karveer Meditech Pvt. Ltd. in India and conducted at Mahatma Gandhi Mission's Medical College & Hospital.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.35%
Tags
-
Rhea-AI Summary
NanoViricides, Inc. (NNVC) to present at Biotech Showcase 2024, highlighting successful Phase 1 clinical trials of NV-CoV-2 Oral Syrup and Oral Gummies drug products containing the novel antiviral nanomachine NV-387, with broad-spectrum antiviral activity across multiple virus families.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.83%
Tags
Rhea-AI Summary
NanoViricides, Inc. (NNVC) reported the successful completion of the Single-Ascending Dose part of the Phase 1a/1b Human Clinical Trial of NV-CoV-2, a broad-spectrum antiviral drug. The drug contains the nanoviricide active agent, NV-387, which has shown strong antiviral activity against coronaviruses, RSV, and Smallpox. The Phase 1a trial in healthy volunteers was completed with no adverse events found. Recruitment for the Multiple-Ascending Dose part was also completed. NV-387 has shown broad-spectrum antiviral activity across multiple virus families, addressing an unmet medical need for a safe and effective antiviral drug. The drug has the potential to revolutionize antiviral treatment and addresses large market sizes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.73%
Tags
-
Rhea-AI Summary
NanoViricides, Inc. (NYSE American: NNVC) - Quarterly Report on Form 10-Q filed, Financial Status, Liquidity Improvement, Drug Pipeline, Platform Technology Expansion, and Market Potential
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.7%
Tags
-
Rhea-AI Summary
NanoViricides, Inc. (AMEX:NNVC) reports that its broad-spectrum antiviral drug candidate, NV-387, was highly effective in an animal model for MPox and Smallpox virus infections. NV-387, currently in Phase 1a/1b human clinical trials for COVID-19 indication in India, has shown strong activity against Seasonal Coronaviruses, SARS-CoV-2, and Respiratory Syncytial Virus (RSV). The drug is designed to mimic a host cell membrane bearing 'Sulfated Proteoglycans' ('S-PG') family of virus attachment receptors, providing a broad spectrum of antiviral activity. Oral NV-387 treatment led to a significant increase in survival lifespan in animal models, indicating its relative effectiveness compared to other drugs. The company believes that NV-387 has the potential to revolutionize the fight against viruses, similar to how antibiotics revolutionized the fight against bacterial infections.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
11.67%
Tags
Rhea-AI Summary
NanoViricides to present at PODD Conference and highlights the potential of its antiviral drug candidate NV-387
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.68%
Tags
-
Rhea-AI Summary
NanoViricides reports successful progress in Phase 1a/1b clinical trial of NV-CoV-2 antiviral drug
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.75%
Tags
-
Rhea-AI Summary
NanoViricides, Inc. reports strong effectiveness of its broad-spectrum antiviral clinical drug candidate NV-387 in an animal model of lethal lung infection with RSV. NV-387 is expected to advance into Phase II human clinical trials for RSV treatment, which will significantly speed up the development of the RSV drug, save costs, and improve ROI.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.64%
Tags
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.54%
Tags
FAQ
What is the current stock price of NanoViricides (NNVC)?
The current stock price of NanoViricides (NNVC) is $1.57 as of January 6, 2025.
What is the market cap of NanoViricides (NNVC)?
The market cap of NanoViricides (NNVC) is approximately 21.2M.
What does NanoViricides Inc. specialize in?
NanoViricides Inc. specializes in discovering, developing, and commercializing drugs for the treatment of viral infections using advanced nanomedicine technologies.
What are the key products in NanoViricides' pipeline?
Key products include HerpeCide™ for herpes-related conditions, FluCide™ for influenza, DengueCide™ for dengue viruses, HIVCide™ for HIV, and NV-387 for various viral infections including RSV, COVID-19, and Influenza.
What recent advancements has NanoViricides made?
Recent advancements include NV-387 demonstrating strong antiviral activity, progressing to Phase II clinical trials for RSV, and showing superior efficacy in preclinical studies compared to existing drugs.
How does NanoViricides' technology work?
Their nanoviricide® drug candidates are designed to mimic host-side features that viruses use to enter cells, making it difficult for the viruses to escape even with mutations.
What financial position was reported by NanoViricides?
As of March 31, 2024, NanoViricides reported a cash balance of approximately $3.51 million, with additional agreements bringing the total available cash to approximately $6 million.
What is NV-387?
NV-387 is a broad-spectrum antiviral drug candidate that has shown strong activity against viruses like RSV, COVID-19, Influenza A, and smallpox/monkeypox. It has completed Phase I trials and is advancing to Phase II.
What is unique about NanoViricides' approach to antiviral therapy?
NanoViricides uses a host-mimetic technology platform that mimics the features viruses use to bind and enter cells, making it highly unlikely for viruses to escape the nanoviricide drugs even with mutations.
Who are NanoViricides' key partners?
NanoViricides collaborates with various external collaborators and consultants, and licenses its technology from TheraCour Pharma Inc. for specific viruses.
How is NanoViricides addressing the COVID-19 pandemic?
NanoViricides has developed NV-387 as a broad-spectrum antiviral with strong activity against COVID-19. Although clinical trials for COVID-19 treatment faced challenges due to the waning pandemic, the company continues to seek non-dilutive funding and focus on further development.
What are the challenges faced by NanoViricides in drug development?
The company faces typical drug development challenges including lengthy processes, substantial capital requirements, and dependence on external collaborators and consultants. Ensuring safety and efficacy in clinical trials remains a critical focus.
NanoViricides Inc.
NYSE:NNVC
NNVC Rankings
NNVC Stock Data
21.23M
13.78M
3.95%
9.42%
2.43%
Biotechnology
Pharmaceutical Preparations
United States of America
SHELTON